Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line S AbuHammad, M Zihlif Genomics 101 (4), 213-220, 2013 | 186 | 2013 |
Narghile (water pipe) smoking among university students in Jordan: prevalence, pattern and beliefs NS Dar-Odeh, FG Bakri, MK Al-Omiri, HM Al-Mashni, HA Eimar, ... Harm reduction journal 7, 1-6, 2010 | 145 | 2010 |
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ... Proceedings of the National Academy of Sciences 116 (36), 17990-18000, 2019 | 87 | 2019 |
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance CA Martin, C Cullinane, L Kirby, S Abuhammad, EJ Lelliott, K Waldeck, ... International Journal of Cancer 142 (10), 2139-2152, 2018 | 61 | 2018 |
Integrative clinical and molecular characterization of translocation renal cell carcinoma Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ... Cell reports 38 (1), 2022 | 50 | 2022 |
Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells M Ahram, E Mustafa, R Zaza, S Abu Hammad, M Alhudhud, R Bawadi, ... Cell Biology International 41 (12), 1345-1355, 2017 | 33 | 2017 |
Predicting recurrent aphthous ulceration using genetic algorithms-optimized neural networks NS Dar-Odeh, OM Alsmadi, F Bakri, Z Abu-Hammour, AA Shehabi, ... Advances and Applications in Bioinformatics and Chemistry, 7-13, 2010 | 32 | 2010 |
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy EJ Lelliott, C Cullinane, CA Martin, R Walker, KM Ramsbottom, ... Scientific reports 9 (1), 1225, 2019 | 27 | 2019 |
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer S Tang, V Sethunath, NY Metaferia, MF Nogueira, DS Gallant, ER Garner, ... Cell reports 38 (8), 2022 | 18 | 2022 |
Flare-up of rheumatoid arthritis by anti-CTLA-4 antibody but not by anti-PD1 therapy in a patient with metastatic melanoma NF Jaberg-Bentele, M Kunz, S Abuhammad, R Dummer Case reports in dermatology 9 (1), 65-68, 2017 | 15 | 2017 |
Inhibitory effects of new mercapto xanthine derivatives in human mcf7 and k562 cancer cell lines HN Sultani, RA Ghazal, AM Hayallah, LK Abdulrahman, K Abu‐Hammour, ... Journal of Heterocyclic Chemistry 54 (1), 450-456, 2017 | 12 | 2017 |
The cellular and molecular effects of the androgen receptor agonist, Cl-4AS-1, on breast cancer cells M Ahram, E Mustafa, S Abu Hammad, M Alhudhud, R Bawadi, ... Endocrine Research 43 (3), 203-214, 2018 | 11 | 2018 |
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway NT Santiappillai, S Abuhammad, A Slater, L Kirby, GA McArthur, ... Cancers 13 (3), 524, 2021 | 8 | 2021 |
CDK4/6 inhibition in cancer: the cell cycle splicing connection KE Sheppard, S AbuHammad Molecular & Cellular Oncology 6 (6), e1673643, 2019 | 6 | 2019 |
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer S Tang, NY Metaferia, MF Nogueira, MK Gelbard, S Abou Alaiwi, J Seo, ... | 3 | 2020 |
PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma LH Chan, P Wang, S Abuhammad, LRJ Lim, J Cursons, KE Sheppard, ... Plos one 18 (11), e0292278, 2023 | | 2023 |
Genome-scale genetic screening identifies PRMT1 as a critical vulnerability in castration-resistant prostate cancer S Tang, N Metaferia, M Nogueira, M Gelbard, S Abou Alaiwi, JH Seo, ... European Journal of Cancer 138, S7, 2020 | | 2020 |
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma (vol 116, pg 17990, 2019) S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ... PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF …, 2020 | | 2020 |
Abstract A061: Targeting PRMT5 enhances the response to CDK4/6 inhibitors in multiple cancer types S AbuHammad, GA McArthur, K Sheppard Molecular Cancer Therapeutics 18 (12_Supplement), A061-A061, 2019 | | 2019 |
Targeting cyclin dependent kinase 4 (CDK4) in melanoma: mechanisms of resistance and novel combination therapies S AbuHammad University of Melbourne, 2018 | | 2018 |